StockNews.AI
JAZZ
StockNews.AI
119 days

Jazz Pharmaceuticals to Report First Quarter Financial Results on May 6, 2025

1. JAZZ to report Q1 2025 results on May 6, 2025. 2. Management will host a live webcast for discussion. 3. Webcast will be accessible from JAZZ's Investors website. 4. Company emphasizes patient-focused innovation in therapeutics. 5. JAZZ has a diverse portfolio in oncology and neuroscience.

Earnings
+0.78%Current Return
VS
+1.59%S&P 500
$103.3804/22 04:38 PM EDTEvent Start
$104.1904/23 11:21 PM EDTLatest Updated
5m saved
Insight
Article

FAQ

Why Neutral?

The scheduled earnings report may influence investor sentiment, but specific results are unknown now.

How important is it?

Upcoming earnings could impact investor expectations and stock price; however, uncertainty exists until results are announced.

Why Short Term?

Earnings reports typically have immediate effects on stock prices; investors will react to results.

Related Companies

N/A
, /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2025 first quarter financial results on Tuesday, May 6, 2025, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. IST to discuss 2025 first quarter financial results and provide a business and financial update.   Audio webcast/conference call:U.S. Dial-In Number: +1 800 715 9871Ireland Dial-In Number: +353 1800 943 926Additional global dial-in numbers are available here.Passcode: 5080203 Interested parties may access the live audio webcast via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. A replay of the webcast will be available via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations.  About Jazz PharmaceuticalsJazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases — often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit www.jazzpharmaceuticals.com for more information. Contacts: Investors:Jeff Macdonald Exec Dir, Investor RelationsJazz Pharmaceuticals plc[email protected]Ireland +353 1 634 3211U.S. +1 650 496 2717 Media:Kristin BhavnaniHead of Global Corporate CommunicationsJazz Pharmaceuticals plc[email protected]Ireland +353 1 637 2141U.S. +1 215 867 4948 SOURCE Jazz Pharmaceuticals plc WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News